COVID-19 vaccine update - 3/17/24

ARC has a limited supply of COVID-19 vaccines from Pfizer for ages 6 months and up. Patients can request the vaccine at already-scheduled visits. You can also schedule online at MyChartARC.com or call 512-272-4636. If online scheduling is not available, please check back frequently as COVID vaccine quantities change.

MyChart Login Help Me Book

Lung Cancer Screening Clinical Study

Austin Regional Clinic physicians constantly work to improve the care given to all our patients. We are dedicated to offering unique options for our patients and helping them reach their ideal health goals. Part of this dedication involves making clinical research available. Clinical research makes it possible to discover the benefits, risks, and safety of commercially available and investigational medications.

Research standards are very strict to help make studies as safe as possible. Teams of government and research experts have already reviewed each study we conduct to minimize any study risks. Austin Regional Clinic has decided to be involved in this research study because we believe it can potentially benefit our patients.

About the lung cancer screening clinical study

Austin Regional Clinic is conducting a research study that will support the development of a blood test to detect early stages of lung cancer for widespread use among individuals.

By participating in this study, you would be contributing to the development of groundbreaking technology with the potential to benefit many people in the future. ARC is one of the many study centers in the United States participating in this research study.

What to expect

We are currently seeking candidates for a clinical research study.

  • This study is expected to last 2 years and will include 3 visits. Your initial visit will involve the first blood draw, followed by a second blood draw at the one-year mark, and a third blood draw during the second year.
  • Neither you nor the study doctor will receive the results of the blood testing as the impact of the Guardant LUNAR-2 test on your health is still under research. The Guardant LUNAR-2 test remains experimental and has not obtained FDA approval for sale.
  • You will be asked to consent to an investigational blood draw.
  • You will be undergoing a low-dose CT scan of the chest for lung cancer screening.

Eligibility criteria

  • Are undergoing or intend to undergo a low-dose CT scan of the chest for lung cancer screening.
  • Between 50 and 80 years old.
  • Have an increased risk of lung cancer. This includes having at least a 20-pack/year smoking history and currently smoking or having quit smoking within the past 15 years.
  • Willing to consent to the investigational blood draw during index low-dose CT scan screening visit and before any invasive procedures or treatment for lung cancer diagnosis.
  • Willing to consent to a 1-year, 2-year, and additional follow-up per protocol.
  • Additional criteria may apply.

Location

Request to participate

For more information on how to participate in this study, please contact our ARC research team at 737-247-7240.